Humanized LL2IGG to Treat Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
This study will examine the safety of a new genetically engineered antibody called hLL2
(epratuzumab) in patients with systemic lupus erythematosus (SLE). It will also evaluate
whether hLL2 can lessen overall disease activity in SLE or kidney damage in patients with
lupus nephritis.
Patients 18 years of age and older with mild to moderately active SLE may be eligible for
this study. Candidates will be screened with blood and urine tests, a chest X-ray,
electrocardiogram (EKG), tuberculin skin test, and screening tests for certain cancers.
All participants will receive weekly infusions of hLL2 for 4 weeks. The drug is given through
a catheter (small plastic tube) placed through a needle in an arm vein. Each infusion takes
about 2 hours, after which the patient is observed in the clinic for 1 to 2 hours before
being discharged from the clinic.
The first 3 patients in the study will receive the lowest of three different doses used in
the study. If this dose is well tolerated, the next 5 patients will receive a higher dose. If
the second dose is tolerated, the last 5 patients will be given the highest dose. If any
serious problems are encountered at a dose, patients in the next group will receive either
the same or lower dose before being advanced to the next level. Patients in the first group
will continue taking prednisone at their regular dose. All other patients will have their
prednisone tapered gradually, if their condition permits. Patients who have a disease flare
may have their prednisone increased for up to 2 weeks, followed by a gradual taper. If the
flare is severe or does not respond to the increased prednisone, the patient will be taken
off the study and treated to control the disease.
Patients will be evaluated at various intervals for up to 8 weeks after the last dose.
Several of the screening tests will be repeated throughout the study. No more than 500 ml of
blood-the equivalent of a single blood donation-will be collected during a 2-month period.
Participants may also be asked to undergo the following optional procedures before starting
treatment, 1 week after the last dose and 8 weeks after the last treatment dose:
- Bone marrow aspiration - to collect cells from the bone marrow. The hip area is
anesthetized and a special needle is used to draw bone marrow from the hipbone.
- Tonsil biopsy - The area to be biopsied is numbed with a local anesthetic and small
pieces of tissue will be removed with a special type of forceps. (The procedure may be
done under general anesthetic.)
- Magnetic resonance imaging (MRI) of the abdomen - The patient lies on a table within a
metal cylinder (the MRI scanner) for about 30 to 40 minutes while images are obtained
with the use of a strong magnetic field and radio waves.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)